323 related articles for article (PubMed ID: 36635516)
1. Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.
Funingana IG; Bedia JS; Huang YW; Delgado Gonzalez A; Donoso K; Gonzalez VD; Brenton JD; Ashworth A; Fantl WJ
Semin Immunopathol; 2023 Jan; 45(1):43-59. PubMed ID: 36635516
[TBL] [Abstract][Full Text] [Related]
2. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
4. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.
Jinawath N; Vasoontara C; Jinawath A; Fang X; Zhao K; Yap KL; Guo T; Lee CS; Wang W; Balgley BM; Davidson B; Wang TL; Shih IeM
PLoS One; 2010 Jun; 5(6):e11198. PubMed ID: 20585448
[TBL] [Abstract][Full Text] [Related]
5. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer.
Yang H; Yu M; Zhong S; You Y; Feng F
J Ovarian Res; 2022 Jan; 15(1):18. PubMed ID: 35093146
[TBL] [Abstract][Full Text] [Related]
6. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
7. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Wong-Brown MW; van der Westhuizen A; Bowden NA
BMC Cancer; 2022 Jan; 22(1):100. PubMed ID: 35073851
[TBL] [Abstract][Full Text] [Related]
8. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
9. Spatial multi-omics analyses of the tumor immune microenvironment.
Hsieh WC; Budiarto BR; Wang YF; Lin CY; Gwo MC; So DK; Tzeng YS; Chen SY
J Biomed Sci; 2022 Nov; 29(1):96. PubMed ID: 36376874
[TBL] [Abstract][Full Text] [Related]
10. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
12. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
13. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
15. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
Brown Y; Hua S; Tanwar PS
Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
[TBL] [Abstract][Full Text] [Related]
17. A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology.
Hu B; Sajid M; Lv R; Liu L; Sun C
Front Immunol; 2022; 13():996721. PubMed ID: 36389765
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
19. Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study.
Thomsen LCV; Kleinmanns K; Anandan S; Gullaksen SE; Abdelaal T; Iversen GA; Akslen LA; McCormack E; Bjørge L
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894472
[TBL] [Abstract][Full Text] [Related]
20. Multiplex Tissue Imaging: Spatial Revelations in the Tumor Microenvironment.
van Dam S; Baars MJD; Vercoulen Y
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
